US 8012944 B2 - Method For Treating Cancer Using Iap Antisense Oligomer And Chemotherapeutic Agent - The Lens - Free & Open Patent and Scholarly Search

Patents

US 8012944 B2

Method For Treating Cancer Using Iap Antisense Oligomer And Chemotherapeutic Agent

Published: Sep 6, 2011
Earliest Priority: Oct 30 2003
Family: 23
Cited Works: 100
Cited by: 13
Cites: 73
Sequences: 490
Additional Info: Cited Works Full text Published Sequence

Abstract

The invention features methods, compositions, and kits for treating a patient having a proliferative disease.

Claims

A method of treating cancer in a patient, said method comprising administering to said patient:
(i) an antisense IAP nucleobase oligomer of between eight and thirty nucleobases in length, the nucleobase oligomer consisting of 5′-NGCACCCNGGANACCANNN-3′ (SEQ ID NO: 151), wherein “N” is “T” or “U” or at least eight consecutive nucleobases thereof; and

(ii) BAY-43-9006, in amounts that together are sufficient to treat said patient.
A method of treating cancer in a patient, said method comprising administering to said patient:
(i) an antisense IAP nucleobase oligomer comprising 5′-NGCACCCNGGANACCANNN-3′ (SEQ ID NO: 151), wherein “N” is “T” or “U”; and

(ii) BAY-43-9006, in amounts that together are sufficient to treat said patient.
The method of claim 2, wherein the antisense IAP nucleobase oligomer and BAY-43-9006 the are administered within 28 days of each other.
The method of claim 2, wherein the antisense IAP nucleobase oligomer and BAY-43-9006 the are administered within 24 hours of each other.
The method of claim 2, wherein the antisense IAP nucleobase oligomer and BAY-43-9006 the are administered within 1 hour of each other.
The method of claim 2, wherein the antisense IAP nucleobase oligomer and BAY-43-9006 the are administered simultaneously.
The method of claim 2, wherein the nucleobase oligomer consists essentially of 5′-UGCACCCTGGATACCAUUU-3′ (SEQ ID NO: 151).
The method of claim 2, wherein the nucleobase oligomer consists of 5′-UGCACCCTGGATACCAUUU-3′ (SEQ ID NO: 151).
The method of claim 2, wherein the nucleobase oligomer is an oligonucleotide.
The method of claim 9, wherein the oligonucleotide comprises at least one modified linkage.
The method of claim 10, wherein the modified linkage is a phosphorothioate linkage.
The method of claim 2, wherein the nucleobase oligomer comprises at least one modified sugar moiety.
The method of claim 12, wherein the modified sugar moiety is a 2′-O-methyl group or a 2′-O-methoxyethyl group.
The method of claim 2, wherein the nucleobase oligomer comprises at least one modified nucleobase.
The method of claim 14, wherein the modified nucleobase is 5-methyl cytosine.
The method of claim 2, wherein the nucleobase oligomer is a chimeric nucleobase oligomer.
The method of claim 16, wherein the nucleobase oligomer comprises DNA residues linked together by phosphorothioate linkages, the DNA residues flanked on each side by at least one 2′-O-methyl or 2-O-methoxyethyl RNA residue.
The method of claim 17, wherein the DNA residues are flanked on each side by at least three 2′-O-methyl or 2′-O-methoxyethyl RNA residues.
The method of claim 18, wherein the DNA residues are flanked on each side by four 2′-O-methyl or 2′-O-methoxyethyl RNA residues.
The method of claim 17, wherein the RNA residues are linked together by phosphorothioate linkages, and the RNA residues are linked to the DNA residues by phosphorothioate linkages.
The method of claim 17, wherein the nucleobase oligomer comprises DNA residues linked together by phosphodiester linkages, the DNA residues flanked on each side by at least two 2′-O-methyl or 2′-O-methoxyethyl RNA residues linked together by phosphorothioate linkages.
The method of claim 21, wherein the DNA residues are flanked on each side by at least three 2′-O-methyl or 2′-O-methoxyethyl RNA residues.
The method of claim 2, wherein the nucleobase oligomer is a Na¹⁹salt comprising eleven DNA residues flanked on each side by four 2′-O-methyl RNA residues, the nucleobase oligomer consisting of 5′-UGCACCCTGGATACCAUUU-3′ (SEQ ID NO: 151), the residues linked together by phosphorothioate linkages.
The method of claim 2, further comprising administering to the patient a chemosensitizer.
The method of claim 2, further comprising administering to the patient a biological response-modifying agent.
The method of claim 2, comprising administering to the patient a second chemotherapeutic agent.
A method of enhancing apoptosis of a cell, the method comprising contacting a cell with a composition comprising: (i) an antisense IAP nucleobase oligomer of between eight and thirty nucleobases in length, the nucleobase oligomer consisting of 5′-NGCACCCNGGANACCANNN-3′(SEQ ID NO: 151), wherein “N” is “T” or “U” or at least eight consecutive nucleobases thereof; and (ii) BAY-43-9006, whereby apoptosis is enhanced.
The method of claim 27, wherein the cell is in vivo.
The method of claim 27, wherein the cell is ex vivo.
The method of claim 1, wherein the cancer is hepatoma.
The method of claim 2, wherein the cancer is hepatoma.
The method of claim 7, wherein the cancer is hepatoma.
The method of claim 8, wherein the cancer is hepatoma.
The method of claim 22, wherein the cancer is hepatoma.
The method of claim 23, wherein the cancer is hepatoma. said proliferative disease.

Owners (US)

Pharmascience Inc (May 27 2011)
Explore more patents:
- View all patents where Owners (US) PHARMASCIENCE INC
Aegera Therapeutics Inc (Apr 04 2005)
Explore more patents:
- View all patents where Owners (US) AEGERA THERAPEUTICS INC

Applicants

Pharmascience Inc
Explore more patents:
- View all patents where Applicants PHARMASCIENCE INC

Inventors

Lacasse Eric
Explore more patents:
- View all patents where Inventors LACASSE ERIC
Mcmanus Daniel
Explore more patents:
- View all patents where Inventors MCMANUS DANIEL
Durkin Jon P
Explore more patents:
- View all patents where Inventors DURKIN JON P

CPC Classifications

C12N15/113
Explore more patents:
- View all patents where CPC Classifications C12N15/113
- View in Classification Explorer
A61K31/337
Explore more patents:
- View all patents where CPC Classifications A61K31/337
- View in Classification Explorer
A61K31/4745
Explore more patents:
- View all patents where CPC Classifications A61K31/4745
- View in Classification Explorer
A61K31/475
Explore more patents:
- View all patents where CPC Classifications A61K31/475
- View in Classification Explorer
A61K31/55
Explore more patents:
- View all patents where CPC Classifications A61K31/55
- View in Classification Explorer
A61K31/7088
Explore more patents:
- View all patents where CPC Classifications A61K31/7088
- View in Classification Explorer
A61K45/06
Explore more patents:
- View all patents where CPC Classifications A61K45/06
- View in Classification Explorer
C12N15/111
Explore more patents:
- View all patents where CPC Classifications C12N15/111
- View in Classification Explorer
C12N2310/11
Explore more patents:
- View all patents where CPC Classifications C12N2310/11
- View in Classification Explorer
C12N2310/315
Explore more patents:
- View all patents where CPC Classifications C12N2310/315
- View in Classification Explorer
C12N2310/321
Explore more patents:
- View all patents where CPC Classifications C12N2310/321
- View in Classification Explorer
C12N2310/341
Explore more patents:
- View all patents where CPC Classifications C12N2310/341
- View in Classification Explorer
C12N2310/346
Explore more patents:
- View all patents where CPC Classifications C12N2310/346
- View in Classification Explorer
C12N2320/31
Explore more patents:
- View all patents where CPC Classifications C12N2320/31
- View in Classification Explorer
A61K2300/00
Explore more patents:
- View all patents where CPC Classifications A61K2300/00
- View in Classification Explorer
C12N2310/3521
Explore more patents:
- View all patents where CPC Classifications C12N2310/3521
- View in Classification Explorer

IPC Classifications

C12N15/11
Explore more patents:
- View all patents where IPC Classifications C12N15/11
- View in Classification Explorer
A61K31/337
Explore more patents:
- View all patents where IPC Classifications A61K31/337
- View in Classification Explorer
A61K31/4745
Explore more patents:
- View all patents where IPC Classifications A61K31/4745
- View in Classification Explorer
A61K31/475
Explore more patents:
- View all patents where IPC Classifications A61K31/475
- View in Classification Explorer
A61K31/55
Explore more patents:
- View all patents where IPC Classifications A61K31/55
- View in Classification Explorer
A61K31/7088
Explore more patents:
- View all patents where IPC Classifications A61K31/7088
- View in Classification Explorer
A61K45/06
Explore more patents:
- View all patents where IPC Classifications A61K45/06
- View in Classification Explorer
C12N15/113
Explore more patents:
- View all patents where IPC Classifications C12N15/113
- View in Classification Explorer

US Classifications

514 44A
Explore more patents:
- View all patents where US Classifications 514 44A
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Sep 6, 2011
US 8012944 B2
Application: Oct 28, 2004
US 97579004 A
Priority: Oct 28, 2004
US 97579004 A
Priority: Oct 30, 2003
US 51626303 P

Download Citation